Lisata Therapeutics, Inc. reported earnings results for the fourth quarter ended December 31, 2022. For the fourth quarter, the company reported net loss was USD 5.99 million compared to USD 6.79 million a year ago. Basic loss per share from continuing operations was USD 0.76 compared to USD 1.7 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.94 USD | -5.77% | -0.68% | +7.69% |
05-20 | Sector Update: Health Care Stocks Softer Late Afternoon | MT |
05-20 | Lisata Therapeutics Receives European Medicines Agency Pediatric Waiver for Pancreatic Cancer Treatment | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+7.69% | 25.92M | |
+43.36% | 58.06B | |
-5.31% | 40.53B | |
+37.52% | 38.99B | |
+14.75% | 26.7B | |
-12.56% | 26.56B | |
-22.45% | 18.98B | |
+0.04% | 12.17B | |
+25.12% | 12B | |
+26.04% | 11.92B |
- Stock Market
- Equities
- LSTA Stock
- News Lisata Therapeutics, Inc.
- Lisata Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2022